Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global acute respiratory distress syndrome therapeutics market was valued at US$ 1.43 billion in 2021 and is expected to register a revenue CAGR of 7.3% to reach US$ 2.63 billion by 2030.

Market Fundamentals

ARDS is a rapidly progressive disease affecting critically ill patients. The major complication in ARDS is fluid leakage into the lungs, making breathing difficult or impossible. It is a severe lung condition that causes low blood oxygen. People with ARDS have another illness or a serious injury, which typically causes fluid to accumulate inside the lungs' small air sacs and surfactant breakdown. Direct or indirect lung injuries fall into one of two types regarding ARDS causes. Some of the direct injuries to the lung include pneumonia, aspiration, and trauma. At the same time, indirect injuries to the lung include inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions. Low blood oxygen levels, fast breathing, and clicking, bubbling, or rattling sounds made by the lungs when breathing are additional indicators of ARDS.

[876387432]

Market Dynamic

Factors driving the revenue growth of the ARDS market include rising levels of air pollution and lifestyle-related diseases and increasing accidents and trauma-related ARDS. The increasing population and rapidly growing usage of personal transportation have led to a considerable rise of harmful gases emitted by vehicles are leading to a rise in air pollution which in turn leads to a rise in respiratory distress. Overall, the increasing incidence of ARDS, better awareness of the disease, and the entry of upcoming ARDS pipeline therapies are expected to boost the market revenue growth during the forecast period. With an increase in the R&D activities in the field and a recent interest in the indication owing to the global coronavirus pandemic, a profound environment is set up to accelerate the uptake of potential emerging therapies with a better clinical profile for ARDS treatment.

Market Ecosystem

The global acute respiratory distress syndrome therapeutics market has been analyzed from three perspectives: type, distribution channel, and region.

Acute Respiratory Distress Syndrome Therapeutics Market by Drug Class

[12312388]

Based on drug class, the global acute respiratory distress syndrome therapeutics market is segmented into bronchodilators, corticosteroids, antimicrobial agents, and others. 

The corticosteroids segment accounts for the largest revenue share in the global market. Corticosteroids are the extensively researched drug for ARDS and the only agents that have shown promise as a potential treatment. They have been investigated as a treatment for ARDS due to their anti-inflammatory and anti-fibrotic properties. 

The bronchodilator segment accounts for the second-largest market revenue share and is expected to grow at a higher CAGR during the forecast period. A bronchodilator is a drug class that relaxes and opens the airways, or bronchi, in the lungs. It works by relaxing the airway muscles. Apart from bronchodilators, corticosteroids, and antimicrobial agents, drug classes like lung surfactants, diuretics, NSAIDs, Anticoagulants, etc., are used to treat ARDS. Diuretics are frequently given to critically ill patients to facilitate liquid removal and have become a pharmacologic adjuvant therapy in patients with ARDS.

Acute Respiratory Distress Syndrome Therapeutics Market by Distribution Channel

Based on distribution channels, the global acute respiratory distress syndrome therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. 

The hospital pharmacy segment is expected to account for the largest revenue share in the global acute respiratory distress syndrome therapeutics market during the forecast period due to favorable reimbursement policies in developed countries and higher patient traffic. Moreover, patients who suffer from ARDS are treated with mechanical ventilation, which is available in hospitals. Hospital pharmacists and doctors are a crucial part of the segment as pharmacists help these patients and provide the best possible care because it is a challenging condition that requires time and attention from professionals.

Acute respiratory distress syndrome Therapeutics Market by Region 

Based on region, the global acute respiratory distress syndrome therapeutics market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

North America dominates the global ARDS therapeutics market with the largest revenue shares due to the improved healthcare infrastructure and increasing ARDS cases. The market revenue growth is fueled by the increasing prevalence of acute lung injury, various ARDS risk factors, and an acceleration in the number of patients with ARDS. The factors influencing the market's revenue expansion are the rising prevalence of acute lung injury, the multiplicity of risk factors for ARDS and acceleration in the number of patients with the disease, and the rise in the number of accidents and traumas result in ARDS. Additionally, the availability of licensed medications is expected to stimulate market revenue expansion.

Competitive Landscape

The prominent players operating in the global acute respiratory distress syndrome therapeutics market are:  

• Akebia Therapeutics, Inc.
• Genentech Inc.
• Boehringer Ingelheim International GmbH
• Chiesi Farmaceutici S.p.A.
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Pfizer Inc.
• Direct Biologics LLC
• HEALIOS K.K.
• Edesa Biotech, Inc.

Strategic Developments

• In December 2022, through the PREPAiRE platform, Tetra Bio-Pharma released findings from the artificial intelligence (AI) study of ARDS-003 and Favipiravir against acute respiratory distress syndrome (ARDS), sepsis and COVID-19.
• In September 2022, Tetra Bio-Pharma and Cellvera agreed to work together to develop ARDS-003 as an oral combination treatment option for COVID-19 that contains 400mg of Qifenda (favipiravir).

Frequently Asked Questions About This Report